Cross-source identity
National Provider Identifier 1285635813 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1285635813 | Registry identity — dermatologist, taxonomy 207N00000X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1285635813 | 299 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1285635813 | 35 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $5,820 | 293 |
| Education | $199 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $88 | 2 |
| Manufacturer | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $1,320 | 61 |
| Abbvie Inc. | $1,230 | 57 |
| Novartis Pharmaceuticals Corporation | $443 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Skyrizi Pen(Risankizumab-Rzaa) | 20 | $410,914 |
| Dupixent Pen(Dupilumab) | 75 | $317,532 |
| Adbry(Tralokinumab-Ldrm) | 31 | $122,769 |
| Otezla(Apremilast) | 20 | $105,573 |
| Cosentyx Sensoready (2 Pens)(Secukinumab) | 11 | $79,217 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
| 19 |
| Incyte Corporation | $344 | 12 |
| Ucb, Inc. | $324 | 19 |